Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying (PDF) China’s CSPC Megalith Biopharmaceutical $15 million upfront for rights to an antibody-drug conjugate (ADC ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback